Eleven Swiss start-ups on the virtual BIO Digital stage

 

Even in the absence of physical presence, trade fairs are taking place in new formats. One of such events is the International Convention BIO, which turned into Bio Digital. At the upcoming online event from 8 -12 June 2020, more than 2300 companies from all over the world and start-ups will attend to learn and forge partnerships. Innosuisse is supporting 11 start-ups to participate in the virtual event.

 

BIO International Convention has transformed into BIO Digital to bring together players in the biotech industry to exchange ideas even in times when it is impossible to gather physically. From 8 - 12 June, more than 2300 companies from all over the world will convene virtually. Through the BIO One-on-One Partnering platform, participants have the opportunity to select and organise a virtual meeting with anyone they would like to interact with, using their desired method - whether that is teleconference system, video meeting service, or another medium. The event also offers educational resources and insights organised in more than 300 Sessions in 17 focus areas including interactive sessions, panel discussions and company presentations.

Start-ups are also among the guests at the BIO Digital. With the Start-up Stadium, the event offers a platform to engage with key members of the investment community, venture philanthropy groups, strategic partners and non-dilutive capital providers. From Switzerland, 11 Swiss start-ups, supported by Innosuisse, will participate in the event. The support depends on the needs of the start-ups and may include for example training for virtual pitching or support in identifying the right partners, initial contacts with the partners and arrangement of 1:1 meetings. All start-ups benefitted from discount on the participation fee.

The eleven selected companies are: 

Alibion (BL)- is developing the first personalised therapy against Rheumatoid arthritis

Anjarium (ZH)- with its Hybridosome platform, the start-up is transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases.

CDR-Life (ZH)- is developing a pipeline of first-in-class tumour-targeted immunotherapies and best-in-class retina disease therapy.

Cellestia Biotech (BS)- first-in-class cancer drugs based on its innovative discovery platform. The drugs target leukaemia, lymphoma and solid tumours.

leadXpro (AG)- a drug discovery company focusing on membrane protein targets such as GPCR’s, ion channels and transporters s

MV BioTherapeutics (TI)– develops live biotherapeutics with multiple human and animal health indications due to adaptive modulation of the gut ecosystem.

NovaGo (ZH)- focuses on the development of regenerative therapies for diseases of the central nervous system such as stroke and spinal cord injury.

SunRegen (BL)- develops neuroprotective drugs for neurodegenerative diseases.

Synendos (BL)- aims to develop safe and effective therapies drugs to treat Posttraumatic Stress Disorder (PTSD), and other mood and anxiety disorders such as depression. 

Topadur (ZH)- is developing innovative drug therapies to treat severe wounds in diabetic patients.

Versantis (ZH)- the ETH Zurich spinoff is specialising in the diagnosis, prevention and treatment of liver diseases

(SK / RAN)